Biovest has developed the AutovaxID™ bioreactor as an ideal production platform (cGMP compliant) for the scalable manufacture of difficult-to-produce biologics including personalized medicines, monoclonal antibodies, cell culture vaccines and therapeutics targeting highly infectious agents. This system’s multiple advantages and benefits have been proven in the production of Biovest’s autologous anti-lymphoma vaccine (BiovaxID®) targeting B-cell blood cancers, representing how automated hollow fiber technology is integral toward providing a robust and dependable commercial process for the manufacture of personalized cancer vaccines.
Magnified views of cells growing on hollow fibers
Cultures Tumor Derived Cells
for Id Protein Production